Literature DB >> 6452475

Direct in vitro evidence for different susceptibilities to 4-hydroperoxycyclophosphamide of antigen-primed T cells regulating humoral and cell-mediated immune responses to sheep erythrocytes: a possible explanation for the inverse action of cyclophosphamide on humoral and cell-mediated immune responses.

T Diamantstein, M Klos, H Hahn, S H Kaufmann.   

Abstract

Suppressor T cells of humoral immune responses, effector T cells mediating DTH, suppressor T cells of DTH, and helper T cells of humoral immune responses, all with specificity to SRBC, were produced in mice. The biologic activity was tested in adoptive transfer experiments. In vitro treatment with different doses of 4-hydroperoxycyclophosphamide (4-HPCy) yielded the result that the various activities tested were not uniformly sensitive to the action of this drug: Suppressor T cells of humoral immune responses and effector T cells mediating DTH were resistant to doses of 4-HPCy that eliminated the activities of suppressor T cells of DTH and helper cells of the humoral immune response. These findings help to explain the various effects cyclophosphamide has on the in vivo immune response and may help to form a basis for the rational manipulation of the immune response by drugs that selectively affect different subgroups of immune cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6452475

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Cell-mediated immunity is enhanced by cytostatic drugs continuously released at the site of antigenic stimulation.

Authors:  A M Claessen; H Valster; H Bril; S Meyer; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  In vitro selective effect of melphalan on human T-cell populations.

Authors:  S Ben-Efraim; L Komlos; J Notmann; J Hart; I Halbrecht
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

3.  The immunological consequences of feeding cholera toxin. I. Feeding cholera toxin suppresses the induction of systemic delayed-type hypersensitivity but not humoral immunity.

Authors:  R A Kay; A Ferguson
Journal:  Immunology       Date:  1989-03       Impact factor: 7.397

4.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.

Authors:  M Comabella; K Balashov; S Issazadeh; D Smith; H L Weiner; S J Khoury
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

5.  In vitro effects of 4-hydroperoxycyclophosphamide on concanavalin A-induced human suppressor T cells.

Authors:  A Klajman; I Drucker; Y Manor; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.

Authors:  T Skórski; M Kawalec
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

7.  Enhancement of cytotoxic T lymphocyte growth from spleens of P815-tumor-bearing host mice with mafosfamide.

Authors:  T H Inge; S K Hoover; J L Frank; T T Kawabata; K P Bethke; H D Bear
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Effects of cyclophosphamide on autoantibody synthesis in the Brown Norway rat.

Authors:  C D Pusey; C Bowman; D K Peters; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

9.  Effect of melphalan in vitro on induction of murine suppressor T cells by ConA.

Authors:  R Ophir; S Ben-Efraim
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Evaluation of various cytostatic drugs as local immunotherapeutic agents.

Authors:  R J Scheper; A Vos; J de Groot; G H Boerrigter
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.